Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 1
A Focused Approach: Targeting Muscarinic Receptors in Schizophrenia

Thu. May 23, 2024 12:30 PM - 1:30 PM Room 1 (Hall C)

Chair: Prakash Masand(Duke-NUS Academic Medicine Education Institute)

Co-sponsored by Bristol Myers Squibb

[CLS1] A Focused Approach: Targeting Muscarinic Receptors in Schizophrenia

*Bristol Myers Squibb

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 2
Current challenges and implications of cognitive performance for clinical practice in the treatment of major depressive disorder

Fri. May 24, 2024 12:15 PM - 1:15 PM Room 2 (Hall B7 (1))

Chair: Hikaru Hori (Faculty of medicine,Department of psychiatry, Fukuoka University)

Co-sponsored by Takeda Pharmaceutical Company Limited / Lundbeck Japan K.K.

[CLS2] Current challenges and implications of cognitive performance for clinical practice in the treatment of major depressive disorder

*Bernhard Baune¹ (1. University of Münster, University of Melbourne, The Florey Institute of Neuroscience and Mental Health)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 3
Potential targets for the treatment of depression: The inflammatory hypothesis.

Fri. May 24, 2024 12:15 PM - 1:15 PM Room 4 (Hall D1)

Chair: Hiroyuki Uchida (Department of Neuropsychiatry, Keio University School of Medicine)

Co-sponsored by Viatris Pharmaceauticals Japan Inc.

[CLS3] Potential targets for the treatment of depression: The inflammatory hypothesis.

*Masaaki Iwata¹ (1. Department of Neuropsychiatry, Brain and Neurosciences, Faculty of Medicine Tottori university)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 4
How to proceed in the management of treat resistant depression -The Possibility of Rexulti-

Fri. May 24, 2024 12:15 PM - 1:15 PM Room 12 (Hall D5)

Chair: Ken Inada (Kitasato University)

Co-sponsored by Otsuka Pharmaceutical Co., Ltd.

[CLS4] How to proceed in the management of treat resistant depression
- The Possibility of Rexulti -

*Masaki Kato¹ (1. Kansai Medical University)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 5
An update on current understanding of tardive dyskinesia: epidemiology, pathology, and burden of patients

Fri. May 24, 2024 12:15 PM - 1:15 PM Room 13 (G701)

Chair: Masaomi Iyo (International University of Health and Welfare Graduate School)

Co-sponsored by Mitsubishi Tanabe Pharma Corporation/Janssen Pharmaceutical K.K.

+Add all to schedule

[CLS5-1] Why was tardive dyskinesia turned a blind eye in psychiatric clinical practice?Learning how to face with patients with tardive dyskinesia from national and international database studies

*Takahiro A. Kato¹ (1. Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University)

[CLS5-2] Impact of Tardive Dyskinesia on Daily Life

*Hiroyoshi Takeuchi¹ (1. Department of Neuropsychiatry, Keio University School of Medicine)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 6
Rethinking medication for schizophrenia

Fri. May 24, 2024 12:15 PM - 1:15 PM Room 14 (G602)

Chair: Kotaro Hatta (Department of Psychiatry, Juntendo University Nerima Hospital )

Co-sponsored by Sumitomo Pharma Co., Ltd.

+Add all to schedule

[CLS6-1] The pharmacotherapy of schizophrenia based on the PET studies

*Amane Tateno¹ (1. Department of Neuropsychiatry, Graduate School of Medicine, Nippon Medical School)

[CLS6-2] User friendly psychopharmacotherapy for schizophrenia:Potential role of transdermal antipsychotics

*Takefumi Suzuki¹ (1. Department of Neuropsychiatry, University of Yamanashi Faculty of Medicine)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 7
Perspective of digital biomarkers in mood disorders

Fri. May 24, 2024 12:15 PM - 1:15 PM Room 15 (G610)

Chair: Taishiro Kishimoto (Hills Joint Research Laboratory for Future Preventive Medicine and Wellness, Keio University School of Medicine)

Co-sponsored by Mochida Pharmaceutical Co., Ltd.

[CLS7] Perspective of digital biomarker in mood disorders

*Yoshikazu Takaesu¹ (1. Department of Neuropsychiatry Graduate Shcool of Medicine University of the Ryukyus)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 8
The New Frontier in Pharmacotherapy for Depression: Moving Beyond the Monoamine Hypothesis

Fri. May 24, 2024 12:15 PM - 1:15 PM Room 16 (G502)

Chair: Yukio Ago (Department of Cellular and Molecular Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University)

Co-sponsored by Shionogi & Co., Ltd.

[CLS8] The New Frontier in Pharmacotherapy for Depression: Moving Beyond the Monoamine Hypothesis

*Hitoshi Sakurai¹ (1. Department of Neuropsychiatry, Kyorin University Faculty of Medicine,)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 9
Disease modifying therapies of Alzheimer's disease

Sat. May 25, 2024 11:40 AM - 12:40 PM Room 1 (Hall C)

Chair: Atsushi Iwata (Tokyo Metropolitan Institute for Geriatrics and Gerontology)

Co-sponsored by Eisai co., Ltd. / BiogenJapan Ltd.

[CLS9] Disease modifying therapies of Alzheimer's disease

*Takeshi Iwatsubo^1,2 (1. Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, 2. National Institute of Neuroscience, National Center of Neurology and Psychiatry)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 10
Challenges and Management of MDD in Working population and Elderly Patients

Sat. May 25, 2024 11:40 AM - 1:00 PM Room 2 (Hall B7 (1))

Chair: Masaki Kato (Department of Neuropsychiatry, Kansai Medical University, Japan)

Co-sponsored by H. Lundbeck A/S

+Add all to schedule

[CLS10-1] What is the optimal way to manage MDD in working individuals?

*Toshiaki Kikuchi¹ (1. Keio University)

[CLS10-2] What can we learn from patient perspectives to improve our approach to treating emotional blunting in MDD?

*Michael MC Wong¹ (1. The University of Hong Kong, Hong Kong SAR)

[CLS10-3] How can we best manage MDD in elderly patients with comorbidities?

*Dong Woo Kang^1,2 (1. The Catholic University of Korea, Seoul, Korea, 2. Seoul St. Mary’s hospital, Seoul, Korea)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 11
Master of Guanfacine -Towards ADHD Treatment Based on Brain Pathophysiology-

Sat. May 25, 2024 11:40 AM - 12:40 PM Room 12 (Hall D5)

Chair: Takashi Tsuboi (Department of Neuropsychiatry, Kyorin University School of Medicine)

Co-sponsored by Takeda Pharmaceutical Company Limited.

[CLS11] Master of Guanfacine -Towards ADHD Treatment Based on Brain Pathophysiology-

*Yasuto Kunii¹ (1. Department of Disaster Psychiatry, International Research Institute of Disaster Science, Tohoku University)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 12
Parkinson’s disease :The approaches to disease modification

Sat. May 25, 2024 11:40 AM - 12:40 PM Room 13 (G701)

Chair: Nobutaka Hattori (Department of Neurology, Juntendo University Faculty of Medicine )

Co-sponsored by Ono Pharmaceutical Co., Ltd.

[CLS12] Parkinson’s disease :The approaches to disease modification

*Kenjiro Ono¹ (1. Department of Neurology, Kanazawa University Graduate School of Medical Sciences)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 13
Treatment strategy for major depressive disorder focusing on anxiety symptoms

Sat. May 25, 2024 11:40 AM - 12:40 PM Room 14 (G602)

Chair: Tempei Otsubo (Department of Psychiatry, Tokyo Women's Medical University Adachi Medical Center)

Co-sponsored by Viatris Pharmaceauticals Japan Inc.

[CLS13] Treatment strategy for major depressive disorder focusing on anxiety symptoms

*Yoshikazu Takaesu¹ (1. Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 14
Future Challenges for Psychiatric Pharmacotherapy

Sat. May 25, 2024 11:40 AM - 12:40 PM Room 15 (G610)

Chair: Nakao Iwata (Department of Psychiatry, Fujita Health University School of Medicine)

Co-sponsored by Sumitomo Pharma Co., Ltd.

[CLS14] Future Challenges for Psychiatric Pharmacotherapy

*Ichiro Kusumi¹ (1. 医療法人奏和会苫小牧緑ヶ丘病院)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 15
Toward Better Clinical Use of Asenapine - An Overview of the Evidence for Asenapine-

Sat. May 25, 2024 11:40 AM - 12:40 PM Room 16 (G502)

Chair: Ken Inada (Department of Psychiatry, Kitasato University School of Medicine)

Co-sponsored by Meiji Seika Pharma Co., Ltd.

[CLS15] Toward Better Clinical Use of Asenapine -An Overview of the Evidence for Asenapine-

*Yoshiteru Takekita¹ (1. Department of Neuropsychiatry, Kansai Medical University)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 16
Evidence and prospect for practice of LAI

Sat. May 25, 2024 11:40 AM - 12:40 PM Room 17 (G510)

Chair: Itaru Miura (Fukushima Medical University)

Co-sponsored by Janssen Pharmaceutical K.K.

[CLS16] Evidence and prospect for practice of LAI

*Fuminari Misawa¹ (1. Yamanashi Prefectural Kita Hospital)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 17
State-of-the-art strategies for diagnosing and treating tardive dyskinesia

Sun. May 26, 2024 12:15 PM - 1:15 PM Room 1 (Hall C)

Chair: Takefumi Suzuki (Department of Neuropsychiatry, University of Yamanashi Faculty of Medicine, Yamanashi)

Co-sponsored by Mitsubishi Tanabe Pharma Corporation / Janssen Pharmaceutical K.K.

[CLS17] State-of-the-art strategies for diagnosing and treating tardive dyskinesia

*John M. Kane¹ (1. Psychiatry and Molecular Medicine at the Donald and Barbara Zucker School of Medicine)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 18
Treatment to cognitive dysfunction in schizophrenia

Sun. May 26, 2024 12:15 PM - 1:15 PM Room 12 (Hall D5)

Chair: Ken Inada (Department of Psychiatry, Kitasato University School of Medicine)

Co-sponsored by Sumitomo Pharma Co., Ltd. Medical Science

[CLS18] Treatment to cognitive dysfunction in schizophrenia

*Hikaru Hori¹ (1. Department of Psychiatry, Faculty of Medicine, Fukuoka University)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 19
Coping with Sleep Disorders: Significance to the Mind, Brain, and Body

Sun. May 26, 2024 12:15 PM - 1:15 PM Room 13 (G701)

Chair: Yoshikazu Takaesu (Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus)

Co-sponsored by Eisai. Co., Ltd.

[CLS19] Coping with Sleep Disorders: Significance to the Mind, Brain, and Body

*Norio Ozaki¹ (1. Pathophysiology of Mental Disorders, Nagoya University Graduate School of Medicine)

Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 20
The Current Status of Hypnotic Prescribing in Japan, Future Challenges and Prospects

Sun. May 26, 2024 12:15 PM - 1:15 PM Room 14 (G602)

Chair: Hitoshi Sakurai (Department of Neuropsychiatry, Kyorin University Faculty of Medicine)

Co-sponsored by MSD K.K.

[CLS20] The Current Status of Hypnotic Prescribing in Japan, Future Challenges and Prospects

*Masahiro Takeshima¹ (1. Department of Neuropsychiatry Akita University Graduate School of Medicine )

Sessions

Co-sponsored Symposium / Seminar » Co-sponsored Luncheon Seminar

Co-sponsored Luncheon Seminar 1A Focused Approach: Targeting Muscarinic Receptors in Schizophrenia

Co-sponsored Luncheon Seminar 2Current challenges and implications of cognitive performance for clinical practice in the treatment of major depressive disorder

Co-sponsored Luncheon Seminar 3Potential targets for the treatment of depression: The inflammatory hypothesis.

Co-sponsored Luncheon Seminar 4How to proceed in the management of treat resistant depression -The Possibility of Rexulti-

Co-sponsored Luncheon Seminar 5An update on current understanding of tardive dyskinesia: epidemiology, pathology, and burden of patients

Co-sponsored Luncheon Seminar 6Rethinking medication for schizophrenia

Co-sponsored Luncheon Seminar 7Perspective of digital biomarkers in mood disorders

Co-sponsored Luncheon Seminar 8The New Frontier in Pharmacotherapy for Depression: Moving Beyond the Monoamine Hypothesis

Co-sponsored Luncheon Seminar 9Disease modifying therapies of Alzheimer's disease

Co-sponsored Luncheon Seminar 10Challenges and Management of MDD in Working population and Elderly Patients

Co-sponsored Luncheon Seminar 11Master of Guanfacine -Towards ADHD Treatment Based on Brain Pathophysiology-

Co-sponsored Luncheon Seminar 12Parkinson’s disease :The approaches to disease modification

Co-sponsored Luncheon Seminar 13Treatment strategy for major depressive disorder focusing on anxiety symptoms

Co-sponsored Luncheon Seminar 14Future Challenges for Psychiatric Pharmacotherapy

Co-sponsored Luncheon Seminar 15Toward Better Clinical Use of Asenapine - An Overview of the Evidence for Asenapine-

Co-sponsored Luncheon Seminar 16Evidence and prospect for practice of LAI

Co-sponsored Luncheon Seminar 17State-of-the-art strategies for diagnosing and treating tardive dyskinesia

Co-sponsored Luncheon Seminar 18Treatment to cognitive dysfunction in schizophrenia

Co-sponsored Luncheon Seminar 19Coping with Sleep Disorders: Significance to the Mind, Brain, and Body

Co-sponsored Luncheon Seminar 20The Current Status of Hypnotic Prescribing in Japan, Future Challenges and Prospects

Authentication

Co-sponsored Luncheon Seminar 1
A Focused Approach: Targeting Muscarinic Receptors in Schizophrenia

Co-sponsored Luncheon Seminar 2
Current challenges and implications of cognitive performance for clinical practice in the treatment of major depressive disorder

Co-sponsored Luncheon Seminar 3
Potential targets for the treatment of depression: The inflammatory hypothesis.

Co-sponsored Luncheon Seminar 4
How to proceed in the management of treat resistant depression -The Possibility of Rexulti-

Co-sponsored Luncheon Seminar 5
An update on current understanding of tardive dyskinesia: epidemiology, pathology, and burden of patients

Co-sponsored Luncheon Seminar 6
Rethinking medication for schizophrenia

Co-sponsored Luncheon Seminar 7
Perspective of digital biomarkers in mood disorders

Co-sponsored Luncheon Seminar 8
The New Frontier in Pharmacotherapy for Depression: Moving Beyond the Monoamine Hypothesis

Co-sponsored Luncheon Seminar 9
Disease modifying therapies of Alzheimer's disease

Co-sponsored Luncheon Seminar 10
Challenges and Management of MDD in Working population and Elderly Patients

Co-sponsored Luncheon Seminar 11
Master of Guanfacine -Towards ADHD Treatment Based on Brain Pathophysiology-

Co-sponsored Luncheon Seminar 12
Parkinson’s disease :The approaches to disease modification

Co-sponsored Luncheon Seminar 13
Treatment strategy for major depressive disorder focusing on anxiety symptoms

Co-sponsored Luncheon Seminar 14
Future Challenges for Psychiatric Pharmacotherapy

Co-sponsored Luncheon Seminar 15
Toward Better Clinical Use of Asenapine - An Overview of the Evidence for Asenapine-

Co-sponsored Luncheon Seminar 16
Evidence and prospect for practice of LAI

Co-sponsored Luncheon Seminar 17
State-of-the-art strategies for diagnosing and treating tardive dyskinesia

Co-sponsored Luncheon Seminar 18
Treatment to cognitive dysfunction in schizophrenia

Co-sponsored Luncheon Seminar 19
Coping with Sleep Disorders: Significance to the Mind, Brain, and Body

Co-sponsored Luncheon Seminar 20
The Current Status of Hypnotic Prescribing in Japan, Future Challenges and Prospects